BIOPHARMA
ByDid Neuroscience Approvals in 2025 Mark a Turning Point—and Set the Stage for a Breakout Year in 2026?
Global – December 2025 — The neuroscience sector experienced a long-anticipated resurgence in 2025, driven by regulatory approvals…
Did Immunology Approvals in 2025 Redefine Autoimmune Care—and Set the Stage for a New Growth Cycle in 2026?
Global – December 2025 — The immunology sector entered a decisive transformation in 2025, marked by major regulatory…
Did Oncology Approvals in 2025 Reshape the Competitive Landscape—and Set the Stage for a Breakthrough Cycle in 2026?
Global – December 2025 — The oncology sector reached a strategic inflection point in 2025, as a surge…
Phase 3 Clinical Trials of Setrusumab in Osteogenesis Imperfecta Fail to Meet Primary Endpoints
London & Novato, Calif. — December 2025 Mereo BioPharma Group plc (NASDAQ: MREO) and Ultragenyx Pharmaceutical Inc. (NASDAQ:…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding AI-Driven Precision Oncology Strategy
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
